89bio, Inc. logo

89bio, Inc.

NASDAQ:ETNB

Overview | Financials
Company Name 89bio, Inc.
Symbol ETNB
Currency USD
Price 10.45
Market Cap 1,106,759,500
Dividend Yield 0%
52-week-range 6.88 - 16.63
Industry Biotechnology
Sector Healthcare
CEO Mr. Rohan Palekar
Website https://www.89bio.com

An error occurred while fetching data.

About 89bio, Inc.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for

Related Stocks

Unity Biotechnology, Inc. logo

Unity Biotechnology, Inc.

UBX

1.17 USD

Pulse Biosciences, Inc. logo

Pulse Biosciences, Inc.

PLSE

19.87 USD

Biodesix, Inc. logo

Biodesix, Inc.

BDSX

1.37 USD

Cryo-Cell International, Inc. logo

Cryo-Cell International, Inc.

CCEL

8.734 USD

Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF

3.08 USD

Sensei Biotherapeutics, Inc. logo

Sensei Biotherapeutics, Inc.

SNSE

0.556 USD

Purple Biotech Ltd. logo

Purple Biotech Ltd.

PPBT

2.81 USD

Financials

Numbers are in millions USD

Numbers are in millions USD